Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: A method of fabricating a semiconductor device includes providing a substrate, forming a target film, a first mask film, a second mask film, and an upper mask pattern on the substrate, forming a first spacer pattern that includes a first line portion and a second line portion, and a folding portion that connects the first line portion and the second line portion, forming a slit mask pattern that partially covers the first spacer pattern, forming a first mask pattern by patterning the second mask film using the slit mask pattern and the first spacer pattern as an etching mask, forming a second spacer pattern, forming a second mask pattern by patterning the first mask film using the second spacer pattern as an etching mask, and forming a plurality of target patterns by patterning the target film using the second mask pattern as an etching mask.

Abstract: A multilayer ceramic electronic component includes a body including a dielectric layer and an internal electrode, and an external electrode disposed on the exterior of the body. The dielectric layer includes a plurality of dielectric grains and a grain boundary present between the dielectric grains. A molar ratio (Al/Ti) of Al and Ti included in the grain boundary satisfies 0.022 to 0.028.

Abstract: A reduced metal powder prepared by processing a waste lithium ion secondary battery to recover valuable metals from the waste lithium ion secondary battery in an economical and environmentally friendly manner is described. To achieve the goal described above, the reduced metal powder according to an embodiment is prepared by pyrolyzing a waste lithium ion secondary battery, and contains metals Ni and Co and has magnetism.

Abstract: There is provided a novel compound of Formula I and a use thereof for the prevention or treatment of a disease associated with SOS1. In one aspect of the present invention, the novel compound is useful for the prevention or treatment of a SOS1 mediated disease such as cancer and RASopathy by inhibiting the interaction between SOS1 and RAS family proteins or between SOS1 and RAC1.

Abstract: A polarizer includes a buffer member and linear metal patterns. The buffer member includes protrusions. Each protrusion has downwardly-increasing width. The buffer member is formed of polymer. The linear metal patterns, spaced apart from each other, are extended in a first direction. Each linear metal pattern covers a respective protrusion.

Abstract: The present disclosure relates to a sensing device and a method for processing sensing data.

Abstract: The present invention relates to a composition for treating neurodegenerative diseases comprising a beta blocker and a cholinesterase inhibitor and, more specifically, to a composition that relieves neuroinflammation, promotes nerve cell differentiation and shows antioxidant effects to exhibit synergistic effects on degenerative neurological diseases.

Abstract: Disclosed is a system operating method of identifying a type of user eating habits to recommend a food and provide a food report, the method including: receiving a request from a user to start chatting with a food recommendation chatbot operated by an account registered to a mobile messenger and providing food report content; presenting questions for identifying the type of user eating habits to the user, and analyzing the type of user eating habits based on responses entered by the user; providing a link to a result of the analyzed type of user eating habits to the user; receiving a request for a food recommendation from the user; providing a list of recommended foods reflecting the analyzed type of user eating habits to the user; providing nutritional information about a food, which is selected by the user from the list of recommended foods, to the user; and making a food report on the selected food and providing a link to the food report to the user, upon a response entered by the user to finally decide th

Abstract: Compositions and methods are described for alleviating, preventing, or treating adverse effects of cholinesterase inhibitors by administering an effective amount of an antioxidant to a subject in need thereof. Composition and methods are described for preventing or treating a brain disease by administering a cholinesterase inhibitor and an antioxidant to a subject in need thereof.

Abstract: A negative electrode for a rechargeable battery and a rechargeable battery including the same, the negative electrode includes a metal substrate including holes therein; a protective layer on the metal substrate, the protective layer including through holes therein overlying and in fluid communication with the holes in the metal substrate; and an electrolyte membrane including a liquid electrolyte layer and a solid electrolyte layer, the liquid electrolyte layer being in the holes and the solid electrolyte layer covering the protective layer and the through holes.

Abstract: Provided is a pharmaceutical composition for preventing or treating lupus-associated disease, including a GIP derivative, a pharmaceutically acceptable salt or solvate thereof, or a long-acting conjugate thereof.

Abstract: Provided is a GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conjugate thereof, or a pharmaceutical composition for preventing or treating diabetes including the same.

Abstract: Provided are a GIP derivative, a pharmaceutically acceptable salt or solvate thereof, or a long-acting conjugate thereof, or a pharmaceutical composition including the same for preventing or treating inflammatory or autoimmune disease.

Abstract: Provided is a pharmaceutical composition for preventing or treating lupus-associated disease, including a glucagon/GLP-1/GIP triple agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conjugate thereof.

Abstract: Provided is a pharmaceutical composition for preventing or treating vasculitis, including a glucagon/GLP-1/GIP triple agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conjugate thereof.

Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.

Abstract: A semiconductor device includes a plurality of first conductive patterns extending parallel in a first direction on a substrate, a plurality of second conductive patterns extending parallel in a second direction crossing the first direction on the substrate, a plurality of buried contacts connected to the substrate between the plurality of first conductive patterns and between the plurality of second conductive patterns, and a landing pad connected to each of the buried contacts on the plurality of buried contacts. The landing pad includes a first side surface extending in the first direction in plan view and a second side surface extending in a third direction in plan view. The third direction is different from the first direction and the second direction in plan view.

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.